Cefazolin and enterobacteriaceae: Rationale for revised susceptibility testing breakpoints

Clinical Infectious Diseases

Volumn 52, Issue 7, 2011, Pages 917-924

  Turnidge, John D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZTREONAM; BETA LACTAMASE; CEFADROXIL; CEFALEXIN; CEFAZOLIN; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; LORACARBEF;

ACUTE PYELONEPHRITIS; AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; CYSTITIS; DISK DIFFUSION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI PNEUMONIA; GRAM NEGATIVE INFECTION; HEALTH CARE ORGANIZATION; HUMAN; IN VITRO STUDY; KLEBSIELLA INFECTION; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; PROTEUS INFECTION; PROTEUS MIRABILIS; PYELONEPHRITIS; SALMONELLA; SEPTICEMIA; SERRATIA INFECTION; SOFT TISSUE INFECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; WILD TYPE;

ANTI-BACTERIAL AGENTS; CEFAZOLIN; ENTEROBACTERIACEAE; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 79953760518     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir031     Document Type: Article

References (30)

1. Ferraro MJ. Should we reevaluate antibiotic breakpoints? Clin Infect Dis 2001; 33(Suppl 3):S227-S229. (Pubitemid 32835795)
2. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; approved standard. Twelfth informational supplement. CLSI Document M100-S20. Wayne, PA: CLSI, 2010.
3. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-2212. (Pubitemid 32531482)
4. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 2007; 20:391-408. (Pubitemid 47175010)
5. Clinical and Laboratory Standards Institute (CLSI). Development of in vitro susceptibility criteria and quality control parameters. Approved guideline, 3rd ed. CLSI Document M23-A3. Wayne, PA: CLSI, 2008.
6. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27:10-22.
7. Kahlmeter G, Jacobsson L. MIC and Zone diameter distributions of wild type microorganisms. Available at: http://www.srga.org/eucastwt/ WT-EUCAST.htm. Accessed 12 October 2010.
8. Turnidge J, Kalhmeter G, Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 2006; 12:418-425.
9. Wiedermann B, Grimm H. Susceptibility to antibiotics: species incidence and trends. In Lorian V, ed. Antibiotics in laboratory medicine, 4th ed. Chapter 19. Baltimore, MD: Williams and Wilkins, 1996.
10. Bell J, Turnidge J. SENTRY antimicrobial surveillance program Asia-Pacific region and South Africa. Commun Dis Intell 2003; 27:S61-S66.
11. Nightingale CH, Greene DS, Quintiliani R. Pharmacokinetics and clinical uses of cephalosporin antibiotics. J Pharm Sci 1975; 64: 1899-1926.
12. Scheld WM, Spyker DA, Donowitz GR, Bolton WK, Sande MA. Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. Antimicrob Agents Chemother 1981; 19:613-619. (Pubitemid 11079469)
13. Madhavan T, Quinn EL, Freimer E, et al. Clinical studies of cefazolin and comparison with other cephalosporins. Antimicrob Agents Che-mother 1973; 4:525-531.
14. Reller LB, Karney WW, Beaty HN, Holmes KK, Turck M. Evaluation of cefazolin, a new cephalosporin antibiotic. Antimicrob Agents Che-mother 1973; 3:488-497.
15. Turck M, Clark RA, Beaty HN, Holmes KK, Karney WW, Reller LB. Cefazolin in the treatment of bacterial pneumonia. J Infect Dis 1973; 128:S382-S385.
16. Lus RG, Calvo MCR, Lopez LG, et al. Treatment with cefazolin in 45 cases or urinary tract infections. Chemotherapy 1997; 23:106-113.
17. Hoyme U, Madsen PO. Cefamandole and cefazolin in the therapy of complicated urinary tract infection. J Infect Dis 1978; 137:S100-S102. (Pubitemid 8344145)
18. Iversen P, Madsen PO. Complicated urinary tract infections treated with cefuroxime or cefazolin: a comparative study. Clin Ther 1981; 4:302-306.
19. Lea AS, Sudan AW, Wood BA, Gentry LO. Randomized comparative study of moxalactam and cefazolin in the treatment of acute urinary tract infections in adults. Antimicrob Agents Chemother 1982; 22:32-35. (Pubitemid 13173859)
20. Millar LK, Wing DA, Paul RH, Grimes DA. Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial. Obstet Gynecol 1995; 86:560-564.
21. Sanchez-Ramos L, McAlpine KJ, Adair CD, Kaunitz AM, Delke I, Brioness DK. Pyelonephritis in pregnancy: once-a-day ceftriaxone versus multiple doses of cefazolin. A randomized, double blind trial. Am J Obstet Gynecol 1995; 172:129-132.
22. Wing DA, Hendershott CM, Debuque L, Millar LK. A randomized trial of three antibiotic regimens for the treatment of pyelonephritis in pregnancy. Obstet Gynecol 1998; 92:249-253. (Pubitemid 28350858)
23. Ries K, Levison ME, Kaye D. Clinical and in vitro evaluation of cefa-zolin, a new cephalosporin antibiotic. Antimicrob Agents Chemother 1973; 3:168-174.
24. Gurwith M, Albritton W, Lank B, Harding G, Ronald A. Prospective comparison of cefoxitin and cefazolin in infections caused by aerobic bacteria. Antimicrob Agents Chemother 1978; 13:255-260. (Pubitemid 8280989)
25. Ribner BS, Raeder R, Hollstein M, Freimer EH. A randomized study comparing clinical efficacy and safety of thienamycin formamidine (MK0787)/renal dipeptidase inhibitor (MK0791) and cefazolin. J An-timicrob Chemother 1983; 13:387-391. (Pubitemid 14232721)
26. Uwaydah M. Cefazolin in the treatment of acute enteric fever. Anti-microb Agents Chemother 1976; 10:52-56.
27. Lewis JS, Jorgensen JH. Successful use of cefazolin therapy for bacteremia with E. coli isolates deemed "resistant" by the new CLSI breakpoints. In: Program and abstracts of the Infectious Disease Society of America annual meeting. Vancouver, BC, Canada: Infectious Disease Society of America, 2010.
28. Cefazolin injection. Available at: http://www.drugs.com/pro/cefazolin- injection.html. Accessed 15 October 2010.
29. Gilbert DN, Moellering RC Jr, Eliopoulos GM, Chambers HF, Saag MS, eds. The Sanford Guide to antimicrobial therapy, 40th ed. Sperryville, VA: Antimicrobial Therapy Inc, 2010.
30. Dien Bard J, Hindler JA, Humphries RM, Lewinski MA. Revised cefazolin breakpoints: potential impact on therapeutic guidance of urinary tract infections. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA: American Society for Microbiology, 2010.